Entrinsic Bioscience and its licensee Nuvara Therapeutics announce they are one step closer to using RxAA formulations as a therapy for patients with Cystic Fibrosis Class I mutations
Entrinsic Bioscience announces a tool to measure intestinal peristalsis that could lead to the development of therapeutic agents for constipation, including Irritable Bowel Syndrome-Constipation (IBS-C).
Entrinsic Bioscience, a pioneering life sciences company incubating at UF Innovate | Accelerate at Sid Martin Biotech, announced results from a new clinical study at renowned Monash University, in Melbourne, Australia. Entrinsic has successfully demonstrated the efficacy of two UF patent-protected formulas, utilizing precise combinations of amino acids, which enabled them to provide targeted gastrointestinal (GI) health and wellness benefits.
UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC's subsidiary, Jefferies Funding LLC (Jefferies).
Why would a doctor specializing in gastrointestinal disorders be interested in therapy for COVID-19, a primarily pulmonary disease? The answer lies in a seemingly convoluted link between the gastrointestinal tract and the lungs: water.